Back to top
more

Biogen (BIIB)

(Delayed Data from NSDQ)

$173.04 USD

173.04
1,581,725

-0.88 (-0.51%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $173.02 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

Earnings Preview: Biogen Inc. (BIIB) Q4 Earnings Expected to Decline

Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen Inc. (BIIB) Stock Moves -1.06%: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $222.31, marking a -1.06% move from the previous day.

Ionis' (IONS) Eplontersen Gets Orphan Drug Tag From FDA

The FDA bestows an Orphan Drug status to Ionis' (IONS) investigational medicine, eplontersen, for treating people living with transthyretin-mediated amyloidosis.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day.

Ionis' (IONS) Partner to Begin New Huntington's Disease Study

Ionis' (IONS) partner, Roche, is planning a new phase II study to evaluate tominersen for the treatment of Huntington's disease.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $239.30 in the latest trading session, marking a +1.11% move from the prior day.

Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

Biotech Stock Roundup: BIIB's AD Drug Update, AMGN's Drug Approval & Other Updates

Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.

Biogen Inc. (BIIB) Stock Moves -1.02%: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $239.27, marking a -1.02% move from the previous day.

Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again

Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Biogen (BIIB) Opts for In-Licensing SMA Therapy From Ionis

Biogen (BIIB) exercises its option to acquire a royalty-bearing license from Ionis to develop and commercialize BIIB115/ION306 for treating spinal muscular atrophy.

Biogen Inc. (BIIB) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $244.14, marking a +1.76% move from the previous day.

Biogen Inc. (BIIB) Stock Moves -0.03%: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $239.92, moving -0.03% from the previous trading session.

Biogen (BIIB) Surges Amid Rumors of Acquisition by Samsung

Biogen (BIIB) stock gains almost 10% on Dec 29 following speculations over its potential acquisition by the South-Korean conglomerate Samsung Group. However, both parties are yet to confirm.

Ekta Bagri headshot

4 Biotechs That Could Be Potential Takeover Targets in 2022

We discuss a few companies like BioMarin (BMRN), Adaptimmune (ADAP), CRISPR Therapeutics (CRSP), and Alnylam Pharmaceuticals (ALNY) with solid product portfolios, deep pipelines which make them attractive candidates for a potential takeover in 2022.

Mark Vickery headshot

Dow, S&P Set Fresh All-Time Closing Highs

Value plays look to have dried up during the past few sessions that account for the front end of the Santa Claus Rally.

Biotech Stock Roundup: Regulatory Updates From NVAX, BBIO Down on Drug Failure & More

Regulatory and other pipeline updates from NVAX and BBIO are among a few key highlights from the biotech sector during the past week.

Ekta Bagri headshot

3 Biotech Stocks Worth Adding to Your Portfolio Next Year

Here we present three biotech companies, which are likely to perform well in 2022, backed by strong fundamentals.

Biogen's (BIIB) Alzheimer's Disease Drug Gets FDA Fast Track Tag

Biogen (BIIB) receives a fast track designation from the FDA for lecanemab to treat Alzheimer's disease.

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed at $235.41 in the latest trading session, marking a +0.4% move from the prior day.

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $234.48, moving -0.07% from the previous trading session.

Biotech Stock Roundup: Regulatory Updates From BIIB, AMGN and NVAX & More

Regulatory and other pipeline updates from Biogen (BIIB) and Novavax (NVAX) have been the biotech sector's few key highlights during the past week.

Biogen (BIIB) to Cut Alzheimer's Drug Aduhelm Price by 50%

Biogen (BIIB) said it is lowering the wholesale acquisition cost (WAC) of Aduhelm by approximately 50%, effective Jan 1, 2022

Biogen (BIIB) to Begin Aduhelm Confirmatory Study in 2022

Biogen (BIIB) expects to start the phase IV post-marketing confirmatory study of Aduhelm for Alzheimer's disease in 2022. It expects to complete the study in four years from the study initiation date.

Biogen Inc. (BIIB) Stock Moves -0.15%: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $235.52, moving -0.15% from the previous trading session.